Form 4 for PLRX PLIANT THERAPEUTICS, INC.
Accepted 2023-01-27 00:00:00 ET · period of report 2023-01-25 · accession 0001140361-23-003180 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-27 | 2023-01-25 | PLRX | Hull Hans | Chief Business Off | A - Grant | $0.00 | +54.0K | 192.2K | +39% | $0 |
| D | 2023-01-27 | 2023-01-25 | PLRX | Hull Hans | Chief Business Off | A - Grant | $0.00 | +76.2K | 76.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-25 | A | A | 54,000 | $0.00 | 192,191 | D | — | — | (F1) These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| 2 | Derivative | Stock Option (right to buy) | 2023-01-25 | A | A | 76,200 | $0.00 | 76,200 | D | $34.65 · — to 2033-01-24 | 76,200 Common Stock | (F5) 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. |